Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: J Pharm Sci. 2016 Dec 20;106(4):1162–1174. doi: 10.1016/j.xphs.2016.12.009

Figure 7.

Figure 7

Data acquired from 18h metabolic cage studies conducted at baseline (pre-treatment) and then at each phase of clofazimine (CFZ; Inline graphic) distribution included (A) the amount of water (mL) consumed (*p<0.0001) and (B) urine (mL) output (*p=0.009) when compared to sham-treated ( Inline graphic) mice. Using the amount (μmole) of urine creatinine (KEGG ID: C00791) measured by 1H- NMR and the corresponding urine volume output (mL), urine creatinine excretion was calculated (C) and was not different between CFZ and sham-treated mice. Food consumed at each time point (D) did not differ between the two groups but the total amount (g) of food consumed was higher in CFZ-treated mice (see text) and CFZ-treated mice did not gain as much body weight (E) as sham-treated mice (*p=0.0002) over the 8-week study. Data are the mean (+SD) of 6 samples per group except for body weight which are 23–24 mice per group.